AbbVie Inc. (ABBV)
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating
AbbVie (ABBV) remains a "Strong Buy" due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline. ABBV's oncology segment is poised for expansion with trispecific antibody ISB 2001 for relapsed/refractory multiple myeloma and Epkinly's third FDA approval. Epkinly's rapid sales growth and multiple ongoing phase 3 studies signal further upside potential in ABBV's oncology pipeline.
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years
The stocks listed below yield between 2.7% and 3.5%. They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is slightly below 2024 levels.
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
2 Dividend Stocks to Hold Through Any Market Cycle
Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face.
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Healthcare Rotation Underway: 3 Stocks Leading the Charge
Is the artificial intelligence revolution hitting its first roadblock? For the first time since the AI boom began in 2023, the industry is starting to feel the weight of expectations, and many of the tech sector's biggest winners have been struggling amidst a volatile market.
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
